SOBI assumes direct responsibility for rare disease drug Orfadin in the USA and Canada

Biotech firm Swedish Orphan Biovitrum (STO: SOBI) has assumed direct responsibility for the distribution of its proprietary product Orfadin (nitisinone) for a rare childhood disease in the USA and Canada.

Orfadin is the only US Food and Drug Administration approved therapy for use as an adjunct to dietary restriction of tyrosine and phenylalanine for the treatment of hereditary tyrosinemia type 1 (HT-1). Sobi has been responsible for the worldwide development and commercialization of Orfadin since 1993 and currently distributes the product in over 50 countries around the globe.

Geoffrey McDonough, chief executive and president, Sobi, said: “We look forward to bringing a global perspective to partnering with genetic and metabolic physicians in serving the tyrosinaemia community in North America.”